ES2070107T3 - Ensayo de antigeno especifico de la prostata (psa) libre y complejado. - Google Patents

Ensayo de antigeno especifico de la prostata (psa) libre y complejado.

Info

Publication number
ES2070107T3
ES2070107T3 ES91913019T ES91913019T ES2070107T3 ES 2070107 T3 ES2070107 T3 ES 2070107T3 ES 91913019 T ES91913019 T ES 91913019T ES 91913019 T ES91913019 T ES 91913019T ES 2070107 T3 ES2070107 T3 ES 2070107T3
Authority
ES
Spain
Prior art keywords
free
aep
psa
complex
specific antigen
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES91913019T
Other languages
English (en)
Other versions
ES2070107T1 (es
ES2070107T5 (es
Inventor
Hans Lilja
Ulf-Hakan Stenman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
STENMAN ULF HAKAN
Original Assignee
STENMAN ULF HAKAN
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20380033&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ES2070107(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by STENMAN ULF HAKAN filed Critical STENMAN ULF HAKAN
Publication of ES2070107T1 publication Critical patent/ES2070107T1/es
Publication of ES2070107T3 publication Critical patent/ES2070107T3/es
Application granted granted Critical
Publication of ES2070107T5 publication Critical patent/ES2070107T5/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Food Science & Technology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

SEGUN EL METODO DE LA INVENCION, SE APLICAN INMUNOENSAYOS PARA MEDIR EL AEP LIBRE ASI COMO UN COMPLEJO INHIBIDOR DE LA PROTEINASA. SEGUN LA INVENCION, EL AEP LIBRE Y EL COMPLEJO AEP SE MIDEN MEDIANTE UN INMUNOENSAYO NO COMPETITIVO UTILIZANDO, AL MENOS, DOS ANTICUERPOS MONOCLONALES DISTINTOS. LA INVENCION SE CARACTERIZA ADEMAS EN TANTO QUE EL COMPLEJO INHIBIDOR DE LA PROTEINASA DE INTERES SE FORMA BIEN CON UNA O1-ANTIQUIMOTRIPSINA, UN INHIBIDOR O1-PROTEASA (IAP) BIEN CON UNA O2-MACROGLOBULINA. ADEMAS, LA INVENCION SE CARACTERIZA EN TANTO QUE EL AEP LIBRE, EL COMPLEJO INHIBIDOR DE PROTEINASA-AEP Y SU RELACION SE APLICAN EN EL DIAGNOSTICO DE PACIENTES CON CANCER DE PROSTATA.
ES91913019T 1990-07-23 1991-07-22 Ensayo de antigeno especifico de la prostata (psa) libre y complejado. Expired - Lifetime ES2070107T5 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9002480 1990-07-23
SE9002480A SE9002480D0 (sv) 1990-07-23 1990-07-23 Assay of free and complexed prostate-specific antigen

Publications (3)

Publication Number Publication Date
ES2070107T1 ES2070107T1 (es) 1995-06-01
ES2070107T3 true ES2070107T3 (es) 1996-04-16
ES2070107T5 ES2070107T5 (es) 2004-05-16

Family

ID=20380033

Family Applications (1)

Application Number Title Priority Date Filing Date
ES91913019T Expired - Lifetime ES2070107T5 (es) 1990-07-23 1991-07-22 Ensayo de antigeno especifico de la prostata (psa) libre y complejado.

Country Status (10)

Country Link
US (4) US5501983A (es)
EP (1) EP0540573B2 (es)
JP (1) JP2669566B2 (es)
AT (1) ATE134448T1 (es)
DE (2) DE69117292T3 (es)
DK (1) DK0540573T4 (es)
ES (1) ES2070107T5 (es)
GR (1) GR3019888T3 (es)
SE (1) SE9002480D0 (es)
WO (1) WO1992001936A1 (es)

Families Citing this family (98)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965379A (en) * 1991-07-19 1999-10-12 Cytimmune Sciences Inc. Method for measuring endogenous cytokines
GB9309966D0 (en) 1993-05-14 1993-06-30 Nordion Int Inc Detection of prostrate-specific antigen in breast tumors
GB9314623D0 (en) * 1993-07-14 1993-08-25 Nordion Int Inc Localization and therapy with agents directed against prostate specific antigen in breast cancer
EP0635575A1 (en) 1993-07-22 1995-01-25 Wallac Oy Monoclonal antibodies against epitopes found in free but not in alpha-1-antichmotrypsin complexed prostate specific antigen
EP0652014A1 (en) * 1993-11-10 1995-05-10 National Institute Of Immunology Treatment of prostatic hypertrophy
US5599677A (en) * 1993-12-29 1997-02-04 Abbott Laboratories Immunoassays for prostate specific antigen
US6143864A (en) * 1994-06-28 2000-11-07 Merck & Co., Inc. Peptides
US5866679A (en) * 1994-06-28 1999-02-02 Merck & Co., Inc. Peptides
US5599686A (en) * 1994-06-28 1997-02-04 Merck & Co., Inc. Peptides
GB9415489D0 (en) * 1994-08-01 1994-09-21 Nordion Int Inc Detection of prostate-specific antigen in amniotic fluid
EP0725139A3 (en) * 1995-02-03 1997-11-26 Bayer Corporation Recombinant prostate-specific antigen and its use as an immunoassay calibrator
US5698402A (en) * 1995-02-23 1997-12-16 Dianon Systems, Inc. Methods for diagnosing benign prostatic hyperplasia
US5614372A (en) * 1995-02-24 1997-03-25 Lilja; Hans Early detection of prostate cancer (CAP) by employing prostate specific antigen (PSA) and human glandular kallikrein (hGK-1)
US5654161A (en) * 1995-05-12 1997-08-05 Chiron Diagnostics Corporation Method for diagnosing prostate cancer
US5807978A (en) * 1995-06-07 1998-09-15 Kokolus; William J. Immunogenic peptides of prostate specific antigen
EP0957749A2 (en) * 1995-09-12 1999-11-24 The General Hospital Corporation Method for early detection of ovarian cancer
US5800347A (en) * 1995-11-03 1998-09-01 The General Hospital Corporation ROC method for early detection of disease
US5710007A (en) * 1995-09-29 1998-01-20 Luderer; Albert A. Methods for diagnosing prostatic adenocarcinoma
EP0855910A4 (en) * 1995-10-18 2000-07-05 Merck & Co Inc Conjugates that can be used to treat benign prostate hyperplasia
EP0789032A2 (en) * 1996-02-01 1997-08-13 Bayer Corporation Method for preparing a monoclonal antibody that provides an equimolar response to free and complexed analyte in a monoclonal/polyclonal sandwich immunoassay
US6143509A (en) * 1996-02-06 2000-11-07 Abbott Laboratories Prostate specific antigen peptides and uses thereof
US6037138A (en) * 1996-04-26 2000-03-14 The Children's Medical Center Corp. Enzyme screen for breast cancer
US6811995B1 (en) 1996-04-26 2004-11-02 Children's Medical Center Corporation Non-invasive enzyme screen for cancer
AU775537B2 (en) * 1996-04-26 2004-08-05 Children's Medical Center Corporation Non-invasive enzyme screen for tissue remodelling-associated conditions
AU4086397A (en) * 1996-09-06 1998-03-26 Centocor Inc. Monoclonal antibodies specific for prostate specific antigen and methods of detecting prostate specific antigen
DE19641560A1 (de) * 1996-10-09 1998-04-16 Boehringer Mannheim Gmbh Monoklonale Antikörper gegen einen Komplex aus humanem ACT und einer Serinprotease
US6107103A (en) * 1996-10-15 2000-08-22 Procyon Bropharma Inc. Assay for PSP94 protein
US6177404B1 (en) 1996-10-15 2001-01-23 Merck & Co., Inc. Conjugates useful in the treatment of benign prostatic hyperplasia
IL121659A (en) * 1996-10-25 2000-07-16 Bayer Ag Method for determining CPSA in a blood sample
US5840501A (en) * 1996-10-25 1998-11-24 Bayer Corporation Determination of cPSA
US5856182A (en) * 1996-11-18 1999-01-05 Beckman Coulter, Inc. Monoclonal antibodies specific for the PSA-ACT complex
US6548260B1 (en) 1997-01-21 2003-04-15 Bayer Corporation Detection of PSA-α2-macroglobulin complex in a biological fluid
US6309816B1 (en) * 1997-04-16 2001-10-30 Horus Therapeutics, Inc. Methods for diagnosing cancer by measuring creatine kinase
DE19717436C2 (de) * 1997-04-25 2001-02-15 Biomac Gmbh Verfahren zur exakten Bestimmung von Prostata-spezifischem Antigen in Körperflüssigkeiten
US7288636B2 (en) * 1997-04-30 2007-10-30 Hybritech Incorporated Forms of prostate specific antigens and methods for their detection
ATE302413T1 (de) * 1997-05-14 2005-09-15 Biosite Diagnostics Inc Schnelle bestimmung des verhältnisses von biologischen molekülen
US6649420B1 (en) 1997-08-26 2003-11-18 Thomas L. Cantor Methods and devices for detecting no-complexed prostate specific I antigen
US5994085A (en) * 1997-08-26 1999-11-30 Cantor; Thomas L. Methods and devices for detecting non-complexed prostate specific antigen
US6300088B1 (en) 1997-11-24 2001-10-09 Duke University Method of detecting prostate specific antigen
DE19814915A1 (de) * 1998-04-03 1999-10-07 Roche Diagnostics Gmbh Immunologisches Verfahren zur Bestimmung von PSA
FI981186A7 (fi) 1998-05-28 1999-11-29 Stenman Ulf Haakan Uusi immunomääritys ja sen käyttö diagnostiikassa
FI981185A7 (fi) * 1998-05-28 1999-11-29 Stenman Ulf Haakan Uusi diagnostinen menetelmä
AU5128799A (en) * 1998-07-24 2000-02-14 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Pb 39, a gene dysregulated in prostate cancer, and uses thereof
US7226731B1 (en) 1998-07-24 2007-06-05 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services PB 39, a gene dysregulated in prostate cancer, and uses thereof
EP1104462B1 (en) 1998-08-10 2007-01-03 Agensys, Inc. Bpc-1: a secreted brain specific protein expressed and secreted by prostate and bladder cancer cells
JP4723725B2 (ja) 1999-04-20 2011-07-13 ターゲット ディスカバリー， インコーポレイテッド 代謝経路を分析するための方法
US6423503B1 (en) * 1999-04-30 2002-07-23 Hybritech Incorporated Forms of free prostate-specific antigen (PSA) and their association with prostate tissues from prostate peripheral zone and transition zone
US6893818B1 (en) * 1999-10-28 2005-05-17 Agensys, Inc. Gene upregulated in cancers of the prostate
FR2807438B1 (fr) * 2000-04-10 2004-09-17 Bio Merieux Nouveaux anticorps reconnaissant specifiquement le psa libre inactif, et leurs applications
GB0012718D0 (en) * 2000-05-24 2000-07-19 Angeletti P Ist Richerche Bio Conjugates of aminodrugs
FR2810114B1 (fr) * 2000-06-13 2002-08-23 Bio Merieux Methode, procede, test immunologique et kit de diagnostic d'un adenocarcinome de la prostate ou d'une hypertrophie benigne de la prostate
DE60138465D1 (de) 2000-07-12 2009-06-04 Agensys Inc Neues tumor antigen das für diagnose und therapie von blasen-, eierstock-, lungen- und nierenkrebs verwendet werden kann
ATE282205T1 (de) 2000-07-24 2004-11-15 Health Research Inc Verfahren zur detektion von prostata-spezifischem membran-antigen in serum
US6379550B1 (en) 2000-07-24 2002-04-30 Health Research, Inc. Method for detecting PSA and its molecular forms using thiophilic gel
US6984494B2 (en) 2000-08-15 2006-01-10 Genentech, Inc. Analytical method
US6863892B2 (en) 2000-08-22 2005-03-08 Agensys, Inc. Nucleic acid and corresponding protein named 158P1D7 useful in the treatment and detection of bladder and other cancers
EP2022797A3 (en) 2000-08-28 2011-11-09 Agensys, Inc. Nucleic acid and corresponding protein entitled 85P1B3 useful in treatment and detection of cancer
US6764825B1 (en) * 2000-10-13 2004-07-20 Tang J. Wang Methods and device for detecting prostate specific antigen (PSA)
US6924358B2 (en) 2001-03-05 2005-08-02 Agensys, Inc. 121P1F1: a tissue specific protein highly expressed in various cancers
US7271240B2 (en) 2001-03-14 2007-09-18 Agensys, Inc. 125P5C8: a tissue specific protein highly expressed in various cancers
EP1573024A4 (en) 2001-04-10 2007-08-29 Agensys Inc NUCLEIC ACIDS AND SUITABLE PROTEINS SUITABLE FOR THE TREATMENT AND EVIDENCE OF VARIOUS CANCER DISEASES
US20030191073A1 (en) 2001-11-07 2003-10-09 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 161P2F10B useful in treatment and detection of cancer
WO2003022995A2 (en) 2001-09-06 2003-03-20 Agensys, Inc. Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
US7842498B2 (en) 2001-11-08 2010-11-30 Bio-Rad Laboratories, Inc. Hydrophobic surface chip
US7534580B2 (en) * 2002-05-01 2009-05-19 Ambrilia Biopharma Inc. PSP94 diagnostic reagents and assays
US20040081653A1 (en) 2002-08-16 2004-04-29 Raitano Arthur B. Nucleic acids and corresponding proteins entitled 251P5G2 useful in treatment and detection of cancer
US20040176577A1 (en) * 2002-09-10 2004-09-09 Eva Rojer Immunoassays for specific determination of SCCA isoforms
EP1563100B1 (en) * 2002-11-01 2013-04-24 Iris Molecular Diagnostics, Inc. Displacement sandwich immuno-pcr
AU2002352976B2 (en) 2002-11-27 2007-11-08 Agensys, Inc. Nucleic acid corresponding protein entitled 24P4C12 useful in treatment and detection of cancer
CA2860151A1 (en) 2003-02-10 2004-08-26 Agensys, Inc. Nucleic acid and corresponding protein named 158p1d7 useful in the treatment and detection of bladder and other cancers
WO2004094652A2 (en) * 2003-04-22 2004-11-04 Neurobiotex, Inc. Zinc-based screening test and kit for early diagnosis of prostate cancer
AU2004263823B2 (en) 2003-05-30 2008-09-18 Agensys, Inc. Prostate stem cell antigen (PSCA) variants and subsequences thereof
RU2381234C2 (ru) 2004-05-28 2010-02-10 Эдженсис, Инк. Антитела и родственные молекулы, связывающиеся с белками psca
DE102004027429B4 (de) 2004-06-04 2018-09-13 Siemens Healthcare Diagnostics Gmbh Verfahren zur Anwendung von auf Markerwerten basierenden Dichtekarten bei der Diagnose von Patienten mit Krankheiten insbesondere von Tumoren
CN101137758B (zh) * 2004-11-03 2012-10-10 意力速分子诊断股份有限公司 均相分析物检测
ES2550177T3 (es) * 2004-11-03 2015-11-05 Iris Molecular Diagnostics, Inc. Microburbujas para concentración de afinidad
US8663600B2 (en) * 2005-02-17 2014-03-04 Diaprost Ab Diagnosis of prostate cancer
US20080125582A1 (en) * 2006-10-13 2008-05-29 Bio-Rad Laboratories, Inc. Methods and compositions for stabilizing prostate specific antigen
US20090088981A1 (en) * 2007-04-26 2009-04-02 Neville Thomas B Methods And Systems Of Dynamic Screening Of Disease
CN103495439B (zh) 2007-05-04 2015-09-16 欧普科诊断有限责任公司 流体连接器和微流体系统
US20090087860A1 (en) * 2007-08-24 2009-04-02 Todd John A Highly sensitive system and methods for analysis of prostate specific antigen (psa)
US8362325B2 (en) 2007-10-03 2013-01-29 Ceres, Inc. Nucleotide sequences and corresponding polypeptides conferring modulated plant characteristics
PL2252893T3 (pl) * 2008-02-21 2014-03-31 Iris Int Inc Sposób wczesnego określenia nawrotu po leczeniu nowotworu gruczołu krokowego
GB2464032A (en) * 2008-05-15 2010-04-07 Soar Biodynamics Ltd Methods and systems for integrated health systems
US20100168621A1 (en) * 2008-12-23 2010-07-01 Neville Thomas B Methods and systems for prostate health monitoring
US20100173791A1 (en) 2009-01-05 2010-07-08 Bio-Rad Laboratories, Inc. Process design using mass spectrometry
ES2812260T3 (es) 2009-02-02 2021-03-16 Opko Diagnostics Llc Estructuras para controlar la interacción de luz con dispositivos microfluídicos
EP2239675A1 (en) 2009-04-07 2010-10-13 BIOCRATES Life Sciences AG Method for in vitro diagnosing a complex disease
CN102346536A (zh) * 2010-07-29 2012-02-08 元太科技工业股份有限公司 省电触控电子书
KR101835918B1 (ko) 2011-03-28 2018-03-07 세키스이 메디칼 가부시키가이샤 Psa의 측정 방법 및 그의 시약
CA2853705C (en) 2011-10-25 2021-10-12 Memorial Sloan-Kettering Cancer Center Free psa antibodies as diagnostics, prognostics and therapeutics for prostate cancer
BR112014013853A2 (pt) 2011-12-09 2020-01-14 Ceres, Inc. uso de um ácido nucleico isolado, método de obtenção de uma célula vegetal transgênica, método de obtenção de uma planta transgênica, método de produção de uma planta, método de produção de biomassa, método de processamento de biomassa, método de alteração da composição de biomassa, método de modulação de composição de biomassa, método de produção de um produto de forragem
JP6308954B2 (ja) 2012-03-05 2018-04-11 オサケユキテュア・アークティック・パートナーズ・アクチボラゲットＯｙ Ａｒｃｔｉｃ Ｐａｒｔｎｅｒｓ Ａｂ 前立腺癌のリスク及び前立腺容積を予測する方法及び装置
CN114740202A (zh) 2014-03-28 2022-07-12 欧普科诊断有限责任公司 与前列腺癌的诊断有关的组合物和方法
US12326453B2 (en) 2014-03-28 2025-06-10 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
EP3253800B1 (en) 2015-03-27 2021-03-03 Opko Diagnostics, LLC Prostate antigen standards and uses thereof
CA2982262A1 (en) 2015-04-29 2016-11-03 Opko Diagnostics, Llc Compositions and methods for active surveillance of prostate cancer
CN108802392A (zh) * 2018-08-29 2018-11-13 上海市东方医院 一种用于诊断前列腺癌的层析试纸条及其制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4446122A (en) * 1979-12-28 1984-05-01 Research Corporation Purified human prostate antigen
EP0042428A4 (en) * 1979-12-28 1982-09-03 Research Corp PURIFIED ANTIGEN OF HUMAN PROSTATE.
US4690890A (en) * 1984-04-04 1987-09-01 Cetus Corporation Process for simultaneously detecting multiple antigens using dual sandwich immunometric assay
AU602861B2 (en) * 1985-03-29 1990-11-01 Hybritech Incorporated Processes for the stabilization of prostate specific antigen in natural matrices
JPH0690203B2 (ja) * 1985-08-23 1994-11-14 中外製薬株式会社 前立腺特異抗原とα▲下１▼−アンチトリプシン複合体の定量方法
US5599677A (en) * 1993-12-29 1997-02-04 Abbott Laboratories Immunoassays for prostate specific antigen
US5599686A (en) * 1994-06-28 1997-02-04 Merck & Co., Inc. Peptides

Also Published As

Publication number Publication date
EP0540573A1 (en) 1993-05-12
DE69117292T3 (de) 2004-06-03
DE69117292T2 (de) 1996-07-18
US5939533A (en) 1999-08-17
EP0540573B1 (en) 1996-02-21
ATE134448T1 (de) 1996-03-15
DE69117292D1 (de) 1996-03-28
GR3019888T3 (en) 1996-08-31
US5912158A (en) 1999-06-15
DK0540573T4 (da) 2004-04-05
EP0540573B2 (en) 2003-11-19
DK0540573T3 (da) 1996-04-09
WO1992001936A1 (en) 1992-02-06
US20020123616A1 (en) 2002-09-05
JP2669566B2 (ja) 1997-10-29
ES2070107T1 (es) 1995-06-01
SE9002480D0 (sv) 1990-07-23
US5501983A (en) 1996-03-26
DE540573T1 (de) 1995-09-28
ES2070107T5 (es) 2004-05-16
JPH06502719A (ja) 1994-03-24

Similar Documents

Publication Publication Date Title
ES2070107T1 (es) Ensayo de antigeno especifico de prostata (psa) libre o complejado.
ES2171676T3 (es) Inmunoensayos por quimioluminiscencia para la deteccion de anticuerpos.
CY1116265T1 (el) Kit ραδιοεπισημανσης και προσδιορισμος δεσμευσης
ES2171219T3 (es) Deteccion precoz de cancer de prostata (cap) por determinacion de una relacion entre las concentraciones de antigeno especifico de prostata (psa) y calicreina glandular humana (hgk-1).
DK0914155T3 (da) Monoklonale antistoffer, der er spepcifikke for det ekstracellulære domæne af prostataspecifikt membran-antigen
DE69731977D1 (de) Spezifische antikörper für dendritische zellen
ES2074062T3 (es) Inmunoensayo para antigenos hiv-1 que utilizan fragmentos de f(ab')2 como sonda.
CY1116133T1 (el) Κλασματα θρομβοσπονδινης (thrombospondin) και χρησεις αυτων σε κλινικες δοκιμες για καρκινο και δημιουργια αντισωματων και αλλων παραγοντων συνδεσης
ATE197052T1 (de) Topiramate-immunoassay, sowie analoge und antikörper
CY1107621T1 (el) Μεθοδος ανιχνευσης αντισωματων σε ενα δειγμα
KR890702039A (ko) 1,25-디하이드록시 비타민 d의 분석 방법
BR0011449A (pt) Método para detectar sìfilis usando antìgenos sintéticos
Pascual et al. Quantification of Ecdysteroids by Immunoassay: Comparison of Encyme Immunoassay and Radioimmunoassay
DK1214447T3 (da) Påvisning af pyruvatkinase-isoenzymer i fæces
SE7714034L (sv) Forfarande for enzymkopplad immunoanalys
MX9708697A (es) Metodo para diagnostico cancer de prostata.
ATE282830T1 (de) Immuntest für human chromogranine a (cga), antikörper, reagenz und dazu geeigneter testsatz
ES2060137T3 (es) Inmunoensayo homogeneo de enzimas.
JP2005533519A (ja) チミジンキナーゼ１活性の測定方法およびその使用
CY1110429T1 (el) Προσδιορισμος
ES2168378T3 (es) Determinacion de tripsinogeno-2 libre y en forma de complejo.
DE69529106D1 (de) Monoklonaler Antikörper gegen denThrombin-Antithrombin III-Komplex und dessen Verwendung in Immunoassays
GR920100123A (el) Αντιδραστήριο πολυχρωματικής κηλίδωσης και μέ?οδος ανάλυσης.
BR0308117A (pt) Dìmeros de avidina eficazes em aumentar a concentração de biotina radioativa em radioimunoterapia pré-direcionada
CO5300499A1 (es) Ensayo de inmunoabsorbente ligado a enzima de inhibicion (elisa) para deteccion y cuantificacion de anticuerpos en muestras biologicas

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 540573

Country of ref document: ES